Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy

• Published in: European journal of cancer care Vol. 29; no. 5; pp. e13268 - n/a
• Main Authors: Abdkarimi, Sina, Razi Soofiyani, Saiedeh, Elham, Goli, Mashhadi Abdolahi, Hossein, Safarzadeh, Elham, Baradaran, Behzad
• Format: Journal Article
• Language: English
• Published: England Hindawi Limited 01-09-2020
• Subjects: Antibodies; Cancer; Cancer immunotherapy; Cancer therapies; Chemotherapy; Combination therapy; CTLA‐4; Health services; immune checkpoint; Immune checkpoint inhibitors; Immune response; Immune system; Immunotherapy; Leukocytes; Nursing; Pancreatic cancer; PD‐1; Regulators; Surgery; Targeted cancer therapy; Tumors; combination therapy; pancreatic cancer; CTLA-4; PD-1; chemotherapy; immune checkpoint
• ISSN: 0961-5423; 1365-2354
• DOI: 10.1111/ecc.13268

Pancreatic cancer is related to a very weak diagnosis; the close parallel between disease incidence and mortality rates from pancreatic cancer reflects the fatal nature of this disease. Although early detection procedures are growing, they are not applicable yet for pancreatic cancer. The majority of cancer patients suffer from advanced disease, in which surgery has no potential effect. Based on the growing evidence, it is predicated that cancer immunotherapy alone or in combination will probably be an essential section of different cancer treatment methods. There are different kinds of immune processes, including various antitumour and tumour‐promoting leukocytes. Moreover, tumour cells utilise numerous approaches to overwhelm the immune response. Use of antibody in the therapeutic protocols is proving significant success and is probably a key element of cancer treatment. This method is directed against numerous negative immunologic regulators and immune checkpoints. In the present review, the clinical outlines of immune checkpoint inhibition are discussed in pancreatic cancer.